A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

NCT07628127 · Not yet recruiting

Last updated 2026-07-12

This clinical trial is testing the safety of an oral medication called VRB-103, either alone or combined with another oral medication called ecnoglutide (VRB-101), in adults who have obesity or are overweight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 336 people Planned (estimated).

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2026-07 · est. completion 2028-03

What this study is testing ClinicalTrials.gov NCT07628127 ↗

Description as written by the study sponsor.

The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

Treatments tested

VRB-103 Drug

VRB-103 tablets will be administered orally.
Placebo Other

Placebo tablets will be administered orally.
VRB-101 also known as Oral Ecnoglutide Drug

VRB-101 tablets will be administered orally.

Main thing measured	Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Sponsor	Verdiva Bio Dev Limited
Conditions studied	Obesity, Overweight
GLP-1 drugs	ecnoglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07628127 ↗